Cell metab:糖尿病和脂肪肝治疗新策略

2015-07-22 佚名 生物谷

                                                        &nb

                                                               

近日,来自美国西南医学中心的研究人员发现降低糖尿病病人和非酒精性脂肪肝病肝脏内一种高浓度的脂质分子可以快速改善胰岛素敏感性。相关研究结果发表在国际学术期刊cell metabolism上。
 
胰岛素是一种重要的激素,能够帮助机体将糖转化为能量,吸收营养同时将多余的糖转化为脂肪。胰岛素敏感性降低会造成这些生理过程的效率下降,导致糖尿病和脂肪肝的发生。
 
西南医学中心的研究人员发现在高脂饮食小鼠模型中过表达酸性神经酰胺酶能够使小鼠的胰岛素敏感性恢复正常水平。当身体内脂肪酸过多而机体不能及时将其消耗,多余的脂肪酸会转变为神经酰胺,而过多的神经酰胺会影响胰岛素信号,导致胰岛素抵抗,进而发生糖尿病和非酒精性脂肪肝。
 
在高脂饮食小鼠模型的肝脏中过表达酸性神经酰胺酶能够防止脂肪肝的发生,同时促进胰岛素在肝脏和脂肪组织内发挥的作用。在脂肪组织内过表达酸性神经酰胺酶也能够防止脂肪肝的发生,并改善系统性胰岛素敏感性。无论是在肝脏还是在脂肪组织内诱导表达酸性神经酰胺酶都会降低肝脏神经酰胺的浓度,这一过程的发生可以使胰岛素敏感性正常化。
 
研究人员还发现多余的神经酰胺会被转化为鞘氨醇,而这两种脂类物质对代谢信号途径具有不同的影响。太多的神经酰胺会导致胰岛素抵抗和炎症的发生,而鞘氨醇则会导致相反的情况发生。
 
总的来说,这项研究发现肝脏和脂肪组织的鞘氨醇之间存在一种快速的交互作用,这对于调节葡萄糖代谢和肝脏对脂类物质的摄取具有重要影响。同时,这项研究还为糖尿病和脂肪肝的治疗提供了重要线索。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887448, encodeId=29c1188e44863, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Aug 15 15:07:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748781, encodeId=7ba31e4878161, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 07 23:07:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895815, encodeId=790c18958151e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jun 11 22:07:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869164, encodeId=8b3e18691643c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 25 12:07:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959418, encodeId=1dbe19594183a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 28 06:07:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478364, encodeId=382714e8364c1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Fri Jul 24 00:07:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2015-08-15 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887448, encodeId=29c1188e44863, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Aug 15 15:07:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748781, encodeId=7ba31e4878161, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 07 23:07:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895815, encodeId=790c18958151e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jun 11 22:07:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869164, encodeId=8b3e18691643c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 25 12:07:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959418, encodeId=1dbe19594183a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 28 06:07:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478364, encodeId=382714e8364c1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Fri Jul 24 00:07:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887448, encodeId=29c1188e44863, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Aug 15 15:07:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748781, encodeId=7ba31e4878161, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 07 23:07:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895815, encodeId=790c18958151e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jun 11 22:07:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869164, encodeId=8b3e18691643c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 25 12:07:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959418, encodeId=1dbe19594183a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 28 06:07:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478364, encodeId=382714e8364c1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Fri Jul 24 00:07:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2016-06-11 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887448, encodeId=29c1188e44863, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Aug 15 15:07:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748781, encodeId=7ba31e4878161, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 07 23:07:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895815, encodeId=790c18958151e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jun 11 22:07:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869164, encodeId=8b3e18691643c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 25 12:07:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959418, encodeId=1dbe19594183a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 28 06:07:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478364, encodeId=382714e8364c1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Fri Jul 24 00:07:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887448, encodeId=29c1188e44863, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Aug 15 15:07:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748781, encodeId=7ba31e4878161, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 07 23:07:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895815, encodeId=790c18958151e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jun 11 22:07:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869164, encodeId=8b3e18691643c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 25 12:07:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959418, encodeId=1dbe19594183a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 28 06:07:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478364, encodeId=382714e8364c1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Fri Jul 24 00:07:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2015-07-28 智智灵药
  6. [GetPortalCommentsPageByObjectIdResponse(id=1887448, encodeId=29c1188e44863, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Aug 15 15:07:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748781, encodeId=7ba31e4878161, content=<a href='/topic/show?id=233a64644ca' target=_blank style='color:#2F92EE;'>#治疗新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64644, encryptionId=233a64644ca, topicName=治疗新策略)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 07 23:07:00 CST 2016, time=2016-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895815, encodeId=790c18958151e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jun 11 22:07:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869164, encodeId=8b3e18691643c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 25 12:07:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959418, encodeId=1dbe19594183a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jul 28 06:07:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478364, encodeId=382714e8364c1, content=<a href='/topic/show?id=d1a55858e70' target=_blank style='color:#2F92EE;'>#新策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58587, encryptionId=d1a55858e70, topicName=新策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da0f7431516, createdName=12498568m52暂无昵称, createdTime=Fri Jul 24 00:07:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]

相关资讯

Circulation:“香水有毒:Say no to含糖饮料”

背景:含糖饮料(SSBs)在全球畅销,过多饮用易导致肥胖。但是,关于目前在全球范围内畅销的含糖饮料,对肥胖相关的心血管疾病(CVD)、肿瘤及糖尿病的影响,尚无在国家、年龄、性别层次进行评估的相关研究。方法与结果:在2010年,我们在年龄/性别层次建立了全球、地区及国家范围内的与饮用含糖饮料相关的疾病模型。关于含糖饮料的消费情况,是从全球各国家有关饮食调查研究中获得的。在心血管疾病(CAD)方面,含

5.5万名2型低收入糖尿病患者将获免费药品

中国初级卫生保健基金会日前在京启动糖尿病患者援助项目,该项目首批覆盖20个城市,预计将有5.5万名2型低收入糖尿病患者享受到免费药品。 据了解,“爱随心达——糖尿病患者援助项目”将为符合项目条件的低保和低收入等两类2型糖尿病患者免费提供由生物制药企业阿斯利康捐赠的艾塞那肽注射液。项目于7月正式启动,援助范围首批覆盖北京、天津、济南、南京、哈尔滨等20个城市。 目前,糖尿病已经成为全球除心脑

Neurology:2型糖尿病可炎性相关脑血流量下降可能与认知功能障碍有关

2型糖尿病可致认知功能障碍研究人员发现,仅仅过去了2年,2型糖尿病患者调节血流量的能力便已降低,由此影响了他们的认知和行为能力。采用队列研究的方法,纳入40名研究对象,19名2型糖尿病患者及21名无糖尿病患者,平均年龄为66岁。19名2型糖尿病患者均已接受5年以上的治疗,平均治疗时间为13年。该研究中,研究人员还对研究对象进行了一系列的测试,评估了他们的认知和记忆功能,同时还使用MRI扫描成像,血

还在幻想着“健康肥胖”?该醒醒了,伙计!

还在幻想着“健康肥胖”?该醒醒了,伙计! 英国的一项新的研究表明,“健康肥胖”只是一个幻想,大多数肥胖的人的身体会随着时间的推移逐渐变差,同时慢慢患上慢性疾病。“‘肥胖矛盾’的理论是指肥胖可能会提高某些人群的生存率,如心力衰竭患者。”伦敦大学学院流行病学和公共卫生系博士生,首席研究员Joshua Bell解释说。但是一项对2500余名英国人的健康进行了20年的追踪观察的研究发现,有一半的人群最初持

PLos Med:糖尿病与阿尔茨海默病关联基础可能与HHEX基因有关

在许多前瞻性基于人群的研究中,人们发现患有2型糖尿病的人群患痴呆和阿尔茨海默病的风险增加(如:J CLIN ENDOCR METAB:糖尿病并发症指向上升的痴呆风险)。相对于不患糖尿病的老年人,患糖尿病的老年患痴呆症风险增加50%。胰岛素降解酶(IDE)是细胞内负责清除胰岛素的酶。胰岛素代谢的变化是胰岛素抵抗的基础。编码IDE的基因位于染色体10 q23-q25,这一区域包括了IDE和HHEX。H

Arthritis Care Res:强化生活干预可防治肥胖相关的膝关节痛

近来发表在Arthritis Care & Research(关节炎治疗与研究)的一篇研究表明,对于超重的成年糖尿病患者,强化生活方式干预(ILI)可以预防膝关节疼痛。 先前一项糖尿病健康研究(Look AHEAD)表明,在基线水平,糖尿病并不增加膝关节疼痛的风险,但是在肥胖糖尿病患者,膝关节疼痛风险很高。来自纽约特拉华大学的White博士及其同事,从Look AHEAD研究中,